Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
ABX-EGF (a monoclonal antibody) Given to Patients with Prostate Cancer with or without Tumor in Other Parts of the Body
This study has been completed.
Sponsored by: | Abgenix
Immunex Corporation
|
---|---|
Information provided by: | Abgenix |
Purpose
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body.
Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.
Condition | Treatment or Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: ABX-EGF |
Phase II |
MedlinePlus related topics: Prostate Cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: A Clinical Trial Evaluating the Safety and Efficacy of ABX-EGF in Patients with Hormone Resistant Prostate Cancer with or without Metastasis
Expected Total Enrollment: 50
Study start: April 2003
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Male
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |